A landmark to toast 900 years of Barts: cancer centre could transform lives
Exclusive: London’s oldest hospital launches campaign to raise money for centre to treat capital’s most vulnerable patients
Source: standard.co.uk
📰 Peter Schmid News
Page 3 - Peter Schmid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Schmid. Real-time updates on events, politics, business and more.
The NHS saved my life, but I'm angry I missed out on this breakthrough treatment
Diagnosed with breast cancer aged 40, I learnt an effective treatment was available – but only to private patients
Source: telegraph.co.uk
The Human Fossil Record Lacks Intermediaries
The news media might be heavily biased toward evolution, but at least it is predictable.
Source: evolutionnews.org
Australopithecines and Confessions of Ignorance
If a few teeth of intermediate size and shape make “the most complete chain of human evolution,” then the evidence for human evolution must be quite modest.
Source: evolutionnews.org
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer
No clinical benefit boost with anti-CD73 oleclumab added to durvalumab and chemo
France General Bruxelles Capitale Laurence Buisseret Peter Schmid Institut Jules Bordet University College London
Source: medpagetoday.com
Inside St Bartholomew's, the world's oldest hospital
As the world-leading hospital approaches its 900th anniversary, its resilient and innovative approach can teach us a lot
Source: telegraph.co.uk
HEALTH NOTES: Thousands more breast cancer sufferers to be given life-saving drug
The UK medicines watchdog the MHRA has now approved the treatment, called Enhertu, as a second line therapy.
Source: dailymail.co.uk
Daiichi Sankyo and AstraZeneca's Enhertu delivers promising trial results
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer - News - PharmaTimes
Source: pharmatimes.com
Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer
More than half of everolimus-treated patients permanently discontinued treatment
City Of United Kingdom Peter Schmid Charles Bankhead European Society For Medical Oncology Leon Berard Center
Source: medpagetoday.com
Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
The event-free survival rate was higher with neoadjuvant pembrolizumab plus chemotherapy, compared with chemotherapy alone.
Peter Schmid Queen Mary University Of London Healthday News New England Journal Queen Mary University Merck Sharp
Source: cancertherapyadvisor.com